Intermountain Health

Running trials

• Recruiting

  A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

  NCT06613360· Phase 1· Source

• Recruiting

  A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

  NCT06619561· Phase 2· Source

• Recruiting

  A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  NCT06586957· Phase 1· Source

• Recruiting

  The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

  NCT06520345· Phase 3· Source

• Active, not recruiting

  TheraSphere With Durvalumab and Tremelimumab for HCC

  NCT05063565· Phase 2· Source

• Recruiting

  Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  NCT05727904· Phase 3· Source

• Recruiting

  Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

  NCT01915511· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.